Short Interest Change: Is Buying Astrazeneca Plc (NYSE:AZN), Having Higher Short Interest a Winning Strategy?

November 25, 2016 - By Vivian Park   ·   0 Comments

Short Interest Change: Is Buying Astrazeneca Plc (NYSE:AZN), Having Higher Short Interest a Winning Strategy?

The stock of Astrazeneca Plc (NYSE:AZN) registered an increase of 8.81% in short interest. AZN’s total short interest was 29.89M shares in November as published by FINRA. Its up 8.81% from 27.47 million shares, reported previously. With 6.95M shares average volume, it will take short sellers 4 days to cover their AZN’s short positions. The short interest to Astrazeneca Plc’s float is 1.31%. About 2.68 million shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has declined 12.39% since April 22, 2016 and is downtrending. It has underperformed by 17.80% the S&P500.

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $66.09 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 27.07 P/E ratio. The Firm has its activities in over 100 countries.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, August 29 by Argus Research. The firm has “Buy” rating by Deutsche Bank given on Monday, September 14. The stock has “Hold” rating given by Nordea on Monday, November 2. On Tuesday, December 1 the stock rating was upgraded by Morgan Stanley to “Overweight”. The rating was upgraded by Oddo & Cie on Tuesday, January 26 to “Top Pick”. Bryan Garnier & Cie upgraded the stock to “Buy” rating in Friday, September 18 report. The company was upgraded on Tuesday, January 19 by Barclays Capital. BNP Paribas downgraded AstraZeneca plc (ADR) (NYSE:AZN) on Wednesday, September 14 to “Neutral” rating. The firm has “Overweight” rating by Piperjaffray given on Friday, September 23. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Hold” rating by HBSC on Monday, February 8.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Businessfinancenews.com which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>